OncoMethylome Sciences Signs Agreement for the Potential use of its technology platform in GlaxoSmithKline Biologicals Immunotherapy Development Program
(Thomson Reuters ONE) -
DURHAM, the United States, and LIEGE, BELGIUM - September 23rd, 2010 -
OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a
leading molecular diagnostics company, announced today that it has entered into
an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use
of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy
development program. Additional financial details were not disclosed.
OncoMethylome's biomarker is stable, highly accurate, and, unlike many other
biomarkers, allows for the analysis of non-invasive tissue samples.
"We are very pleased to enter into this agreement with GSK. This project was
initiated in 2007 and is a prime example of how we can bring our considerable
regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D.,
Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an
important step for our company in the use of our biomarker with certain
immunotherapeutics in development by GSK, and underpins our strategy of
leveraging our methylation specific PCR platform in the rapidly emerging field
of companion diagnostics and personalized medicine."
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that
commercializes and develops tests to assist physicians in detecting and treating
cancer. The company's tests are based on proprietary gene methylation technology
and are designed to help the physician accurately detect early stages of cancer,
predict a patient's response to drug therapy, and predict the likelihood of
cancer recurrence. OncoMethylome Sciences collaborates with leading cancer
research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of
commercial and collaborative partnerships with LabCorp, Schering-Plough,
GlaxoSmithKline Biologicals, Roche, Merck Serono and Qiagen.
For more information:
Dr. Jan Groen
CEO
Telephone (+32) 4.364.20.70
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of OncoMethylome and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different. OncoMethylome expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
[HUG#1446057]
2010-09-23 GSK ENG:
http://hugin.info/137314/R/1446057/389121.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OncoMethylome Sciences via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 23.09.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 42954
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome Sciences Signs Agreement for the Potential use of its technology platform in GlaxoSmithKline Biologicals Immunotherapy Development Program"
steht unter der journalistisch-redaktionellen Verantwortung von
OncoMethylome Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
